Zenosense, Inc. (ZENO) Steadily Progressing Toward Commercialization of a Low Cost, Rapid Detection Device for Both MRSA & Lung Cancer
Zenosense has posted some solid news in the last two months on the progress of their rapid detection sensor technology for sniffing out MRSA/SA Super-Bug (Methicillin-resistant Staphylococcus aureus) and lung cancer from patient's breath. Devices whose advent could create a paradigm shift in currently costly, time-consuming and/or dangerous testing methodologies. Late last month, the company was proud to report that their MRSA/SA detector prototype successfully scored a 95% plus detection rate in clinical testing, with key circuit board integration advancement also occurring, including a powerful solid-state processor and low power piezoelectric (electric charge created through applied mechanical stress on certain…